EMT is a fundamental developmental program that is hijacked in cancer. During EMT, cells lose the apical-basal polarity and cell-cell adhesion molecules, such as E-cadherin, that hold epithelial sheets together, and they instead express mesenchymal markers including N-cadherin, vimentin, and transcriptional repressors of the Snail, Slug, Twist, and Zeb families. In lung biology, this program is deeply implicated in both pathological fibrosis and carcinoma progression, since the same signaling cascades that mobilize epithelial plasticity during wound repair can be co-opted by tumor cells to detach, migrate, invade surrounding tissue, and ultimately seed metastases. Transforming growth factor beta, or TGF-β, is the most potent and widely studied inducer of EMT, activating downstream SMAD-dependent transcription as well as non-canonical pathways involving MAPK, PI3K-AKT, and Rho GTPases.

What has become increasingly clear over the past decade is that EMT is not merely a change in gene expression; it is a wholesale reorganization of cellular metabolism. Epithelial cells, which rely heavily on mitochondrial oxidative phosphorylation to generate ATP, must rewire their energetic machinery to support the demanding biosynthetic needs of a migrating, proliferating cell. Aerobic glycolysis provides rapid ATP and, critically, diverts glycolytic intermediates into branching anabolic pathways, including the pentose phosphate pathway for nucleotide synthesis and serine biosynthesis routes for lipid and amino acid generation. This metabolic flexibility is thought to be a prerequisite for successful EMT rather than simply a byproduct of it, and teasing apart cause from consequence is precisely the challenge that the new work addresses.

The research team focused on lung epithelial cells because the lung represents a clinical arena in which EMT-linked processes carry enormous weight. Idiopathic pulmonary fibrosis involves fibroblast activation and epithelial cell state transitions driven in part by TGF-β, while lung cancers, including non-small cell lung carcinoma, frequently display hybrid epithelial-mesenchymal phenotypes associated with drug resistance and metastatic spread. Understanding whether glycolytic reprogramming is a driver or a passenger in the TGF-β-induced transition of lung epithelial cells therefore has implications that extend from basic cell biology to therapeutic strategy, because metabolic enzymes are, in principle, druggable targets in a way that master transcription factors often are not.

Technically, the investigation combined TGF-β stimulation of lung epithelial cell models with measurements of glycolytic flux, lactate production, and the expression of key glycolytic enzymes such as hexokinase 2, phosphofructokinase, and lactate dehydrogenase A. These functional readouts were integrated with assessments of EMT marker expression, including the loss of E-cadherin and the gain of vimentin and N-cadherin, to establish a temporal and causal relationship between metabolic shift and phenotypic conversion. Such paired metabolic and molecular phenotyping is essential because TGF-β is known to alter numerous cellular processes simultaneously, and only carefully timed interventions can reveal which changes are required for EMT to proceed and which are secondary consequences of it.

The broader literature supports the plausibility of a causal link. Hypoxia-inducible factor 1 alpha, a master regulator of glycolytic gene expression, is stabilized not only by low oxygen but also by TGF-β signaling through mechanisms involving reactive oxygen species and mTOR pathway activation. At the same time, TGF-β suppresses the expression of PPAR gamma coactivator 1 alpha, a key driver of mitochondrial biogenesis, thereby tilting the balance away from oxidative metabolism. Glycolytic enzymes themselves have been reported to moonlight as transcriptional co-regulators; for example, certain glycolysis-associated factors can influence the activity of EMT transcription factors, creating feedback loops in which metabolism and gene expression reinforce one another. If such loops operate in lung epithelial cells, blocking glycolysis could potentially arrest or reverse the EMT program rather than merely slowing cellular energy production.

Therapeutically, the implications are considerable. Drugs that target glycolysis, ranging from hexokinase inhibitors to lactate dehydrogenase inhibitors, have been explored in preclinical cancer models for years, although clinical translation has been complicated by the dependence of normal tissues, including the brain and red blood cells, on glucose metabolism. The value of the new work lies in narrowing the therapeutic window: if glycolytic dependency is specifically induced during the EMT transition in lung epithelial cells, then transient metabolic intervention could be timed to coincide with windows of tumor plasticity, such as during the emergence of resistance to targeted therapies or immune checkpoint inhibitors, when EMT-associated states are thought to be most prominent.

The study also speaks to a conceptual shift in how the field understands cell state transitions. EMT is now recognized not as a binary switch but as a spectrum of hybrid states, with cells occupying partial epithelial-mesenchymal phenotypes that may be particularly aggressive and drug tolerant. Metabolic profiling adds an additional axis to this landscape: hybrid cells may display intermediate glycolytic dependency, fully mesenchymal cells may be the most glycolytic, and reversibility of the process may depend on whether the metabolic reprogramming has been consolidated through epigenetic modification. Stable chromatin changes at EMT gene loci could lock in a mesenchymal state even after the original TGF-β signal dissipates, suggesting that metabolic interventions would need to occur early in the transition to be effective.

For patients with lung disease, the distance between mechanistic cell biology and clinical benefit remains substantial, and the authors’ findings should be understood as foundational rather than immediately actionable. Nevertheless, the convergence of TGF-β biology, metabolic reprogramming, and epithelial plasticity in lung cells offers a coherent framework for developing biomarkers that identify patients whose tumors or fibrotic lesions are undergoing active EMT, and for designing combination regimens in which metabolic inhibitors sensitize cells to existing TGF-β pathway antagonists, kinase inhibitors, or antifibrotic agents. As the field continues to map the metabolic architecture of cell state transitions, studies like this one bring the goal of intervening in cancer progression and fibrosis at the level of cellular identity, rather than merely cellular proliferation, steadily closer to realization.

Subject of Research: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article Title: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article References: Huang, S.-W., Chen, H.-C., Peng, S.-Y., Chuang, C.-H., Chen, B.-C., Cheng, W.-H., Cools, J. M. T., Neoh, M.-M., Hsiao, S.-H., & Hsu, M.-J. (2026). The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03322-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03322-5

Keywords: aerobic glycolysis, Warburg effect, TGF-beta, epithelial-to-mesenchymal transition, lung epithelial cells, EMT, cancer metastasis, metabolic reprogramming, lactate dehydrogenase, pulmonary fibrosis, cell death discovery, glycolytic flux

PFKL is one of the most important regulatory proteins in the pathway that converts glucose into usable cellular energy. Glycolysis takes place in the cytoplasm and breaks one molecule of glucose into two molecules of pyruvate, producing ATP while also generating metabolic intermediates needed to make nucleotides, amino acids and lipids. The reaction controlled by phosphofructokinase is especially significant because it acts as a metabolic checkpoint. Once glucose-derived carbon passes through this stage, the cell is strongly committed to processing it through glycolysis.

Cancer cells frequently alter this pathway. Many tumors consume glucose at unusually high rates even when oxygen is available, a phenomenon historically associated with the Warburg effect. This metabolic reprogramming does not simply provide energy. It gives malignant cells flexible access to the molecular building blocks required for DNA replication, membrane production and rapid division. Because glycolysis is so central to tumor biology, enzymes within the pathway have long attracted attention as possible drug targets. The challenge has been finding a way to interfere with cancer metabolism without causing unacceptable damage to healthy tissues.

The new work takes an unusual approach. Instead of blocking PFKL, the researchers developed a molecule that activates it. The compound forms a covalent interaction with the enzyme, creating a chemically stable attachment at a specific site on the protein. Covalent drugs can offer prolonged target engagement because the compound remains linked to its target after the initial binding event. That feature may be especially useful for enzymes whose activity needs to be shifted persistently rather than temporarily.

Activating PFKL can push glucose metabolism forward, but increased pathway activity does not necessarily benefit a tumor. Glycolysis is a network governed by tightly balanced flows of carbon, energy and signaling molecules. Driving one control point beyond the range that cancer cells can accommodate may create metabolic stress. Excessive glycolytic activity can alter the levels of upstream and downstream metabolites, disturb cellular energy management and intensify dependence on nutrients or pathways that tumors cannot easily replace.

The reported compound, therefore, appears to exploit a vulnerability created by cancer’s metabolic ambition. Tumor cells may be heavily invested in high-rate glucose consumption, yet that dependence can become a liability when the pathway is forcibly accelerated. A covalent PFKL activator could act like a metabolic accelerator that pushes malignant cells beyond a tolerable operating limit. Rather than starving tumors by removing glucose, the strategy aims to make their existing glucose-processing program harmful to their survival.

This concept is notable because most efforts to target cancer metabolism have focused on inhibition. Blocking glycolysis can reduce ATP production or deprive cells of biosynthetic intermediates, but normal tissues also rely on glucose metabolism, creating potential toxicity concerns. Enzyme activation offers a different therapeutic logic: selectively destabilizing the metabolic state on which tumor cells depend. The success of this approach will depend on how strongly the compound affects PFKL in cancer compared with healthy cells, as well as how different tumor types manage the resulting metabolic pressure.

The study’s title indicates that the activator suppressed tumor growth, a finding that moves the concept beyond biochemical enzyme assays. To establish whether such a molecule can become a practical therapy, researchers will need to define its selectivity, pharmacological behavior, distribution through the body and safety profile. They will also need to determine whether tumors can adapt by reducing glucose uptake, switching to alternative fuels or altering the expression of other glycolytic enzymes. Cancer cells are remarkably capable of rewiring metabolism, and resistance mechanisms will be a central question for future work.

The covalent nature of the compound also makes careful chemical characterization essential. A useful covalent drug must react efficiently with its intended protein while minimizing unwanted modification of other cellular proteins. Researchers typically examine target engagement, proteome-wide selectivity and the durability of the biological response. These studies can reveal whether the compound’s effects arise primarily from PFKL activation or from broader chemical reactivity. If the molecule demonstrates a favorable selectivity profile, it could provide a framework for developing additional covalent activators against metabolic enzymes.

The findings place PFKL in a growing category of drug targets whose therapeutic potential may lie not in shutting them down, but in pushing them into an abnormal state. By turning a central glycolytic control point against cancer cells, the researchers have highlighted a strategy that combines chemical biology with the emerging science of metabolic stress. The work does not mean that a new cancer treatment is immediately available, but it offers a provocative blueprint: sometimes the most effective way to attack a tumor’s fuel system may be to make it burn too intensely to survive.

Subject of Research: Cancer metabolism and covalent activation of phosphofructokinase L (PFKL) to suppress tumor growth

Article Title: A covalent PFKL activator suppresses tumor growth

Article References: Jiang, X., Lynch, E.M., Lyu, C. et al. “A covalent PFKL activator suppresses tumor growth.” Nature Chemical Biology (2026). https://doi.org/10.1038/s41589-026-02289-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41589-026-02289-9

Keywords: cancer metabolism, PFKL, phosphofructokinase, glycolysis, covalent activator, tumor growth, metabolic stress, chemical biology, cancer therapeutics